Human Genome Sciences has rejected British pharmaceutical giant GlaxoSmithKline's unsolicited $2.59 billion takeover bid. Cleary and Wachtell are advising Glaxo, while Skadden and DLA are working with the target company.
Font Size: 
Six Am Law Firms Land Roles on GSK's $2.59 Billion Hostile Biotech Bid
The Am Law Daily
April 19, 2012
This content is now available at LexisNexis®.
The ALM® and LexisNexis® Content Alliance
LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM’s legal news publications. LexisNexis® customers will be able to access and use ALM’s content by subscribing to the LexisNexis® services via lexis.com® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM’s other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.
ALM’s content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.
If you are not currently a LexisNexis subscriber, contact 1-800-227-4908 to find out more or click here to have a customer representative contact you directly.
